Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ADMA BiologicsADMA +0.39%64 Intrinsic Value: Projected FCF is $0.77 as of Sep. 17, 2026. GuruFocus rates ADMA with a GF Score™ of 64/100 and a GF Value™ of $18.38 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 257 Biotechnology companies, ADMA Biologics ranks worse than 87.16% on this metric.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2026-09-17), ADMA Biologics's Intrinsic Value: Projected FCF is $0.77. The stock price of ADMA Biologics is $8.95. Therefore, ADMA Biologics's Price-to-Intrinsic-Value-Projected-FCF of today is 11.6.
The historical rank and industry rank for ADMA Biologics's Intrinsic Value: Projected FCF or its related term are showing as below:
ADMA'
s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 10.87 Med: 37.62 Max: 64.36
Current: 11.62
During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of ADMA Biologics was 64.36. The lowest was 10.87. And the median was 37.62.
ADMA's Price-to-Projected-FCF is ranked worse than 87.16% of 257
companies
in the Biotechnology industry
Industry Median: 2.12
vs ADMA: 11.62
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
ADMA Biologics's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
8.95
/
0.77744949292157
=
11.51
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADMA Biologics Intrinsic Value: Projected FCF Related Terms
ADMA Biologics Intrinsic Value: Projected FCF Historical Data
* Premium members only.
The historical data trend for ADMA Biologics's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADMA vs VCEL, COAG, KLRA: Intrinsic Value: Projected FCF Comparison
For the Biotechnology subindustry, ADMA Biologics's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADMA Biologics Price-to-Projected-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ADMA Biologics's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where ADMA Biologics's Price-to-Projected-FCF falls into.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Intrinsic Value: Projected FCF of $0.77 mean?
ADMA Biologics (ADMA) has a Intrinsic Value: Projected FCF of $0.77 as of Sep. 17, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on ADMA Biologics and its competitors. According to the industry distribution chart, ADMA Biologics ranks #224 out of 257 companies in the Biotechnology industry, placing it in the top 87.2%.
Is ADMA Biologics' Intrinsic Value: Projected FCF too high?
ADMA Biologics' current Intrinsic Value: Projected FCF is $0.77. The Biotechnology industry median Intrinsic Value: Projected FCF is 2.12. ADMA Biologics' value of $0.77 is 63.7% below this industry median. Based on the distribution chart, ADMA Biologics ranks #224 out of 257 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ADMA Biologics has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ADMA Biologics' Intrinsic Value: Projected FCF compare to VCEL and COAG?
According to the Biotechnology industry distribution chart, ADMA Biologics ranks #224 out of 257 companies for Intrinsic Value: Projected FCF. This places ADMA Biologics in the lower half of its industry. The industry median Intrinsic Value: Projected FCF is 2.12. ADMA Biologics' value of $0.77 is 63.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Biotechnology company?
The median Intrinsic Value: Projected FCF among Biotechnology companies is 2.12, based on 257 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ADMA Biologics's current Intrinsic Value: Projected FCF of $0.77 is 63.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on ADMA Biologics and its competitors. For the Biotechnology industry, the median Intrinsic Value: Projected FCF is 2.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ADMA Biologics's current Intrinsic Value: Projected FCF is $0.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADMA Biologics stock overvalued right now?
Based on GuruFocus' analysis, ADMA Biologics (ADMA) is currently considered Significantly Undervalued. The stock's GF Value™ is $18.38, compared to a current price of $8.95 — trading 51.3% below its estimated fair value. The current Intrinsic Value: Projected FCF is $0.77 and 63.7% below the Biotechnology industry median of 2.12. ADMA Biologics' overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For ADMA Biologics (ADMA), the current Intrinsic Value: Projected FCF is $0.77 as of Sep. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ADMA Biologics (ADMA) Overvalued in 2026?
Based on GuruFocus' analysis, ADMA Biologics stock appears to be undervalued.
The current stock price of $8.95 is trading 51.3% below its estimated GF Value™ of $18.38.
GuruFocus considers ADMA Biologics to be Significantly Undervalued.
Key valuation signals for ADMA:
Intrinsic Value: Projected FCF: $0.77
GF Value™: $18.38 vs. price of $8.95 (51.3% below fair value)
Industry Position: 63.7% below the Biotechnology median (#224 of 257)
No single metric tells the full story. See the ADMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
64GF Score
Get the complete analysis for ADMA
Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADMA has been successfully added to your 
